

Special Issue

The Sphingolipid Pathway in Cancer

Message from the Guest Editors

Sphingolipids have long been known to play critical roles in the properties of cellular membranes. Research over the last three decades, however, has shown a number of sphingolipids to also be important signaling molecules that regulate a wide array of biological processes. In particular, sphingolipids, including but not limited to the ceramides and sphingosine 1-phosphate, have been shown to be important regulators of cell fate, influencing cell survival and proliferation, as well as cell differentiation. For this reason, the sphingolipid pathway has garnered significant interest as a target for anticancer therapies. This Special Issue of *Cancers* seeks reviews and original papers that examine the roles of the sphingolipid pathway and its various individual components in cancers. The objective is to highlight the current understanding of the regulation of sphingolipid metabolism and signaling, its impact on cancer initiation, progression and responses to therapy, including chemoresistance, and how this information may be exploited for therapeutic benefit.

Guest Editors

Prof. Dr. Stuart M. Pitson

Prof. Nigel Pyne

Dr. Melissa Pitman

Deadline for manuscript submissions

closed (30 November 2019)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/25083

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)